Innate Pharma S.A. (IPHYF)
OTCMKTS · Delayed Price · Currency is USD
1.450
-0.310 (-17.61%)
At close: Apr 11, 2025

Innate Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
167166233282400334
Upgrade
Market Cap Growth
-29.08%-29.08%-17.19%-29.50%19.60%-36.34%
Upgrade
Enterprise Value
111107180196283177
Upgrade
Last Close Price
1.452.902.843.274.354.18
Upgrade
PS Ratio
8.047.953.434.5814.243.92
Upgrade
PB Ratio
18.3118.114.074.873.271.75
Upgrade
P/TBV Ratio
18.3118.114.105.025.562.49
Upgrade
EV/Sales Ratio
4.865.152.653.1910.072.07
Upgrade
EV/EBITDA Ratio
-----10.86
Upgrade
EV/EBIT Ratio
-----133.87
Upgrade
EV/FCF Ratio
-14.71-----
Upgrade
Debt / Equity Ratio
3.513.510.770.780.410.12
Upgrade
Debt / EBITDA Ratio
-----1.33
Upgrade
Asset Turnover
0.140.140.310.240.090.20
Upgrade
Quick Ratio
2.602.603.513.211.673.64
Upgrade
Current Ratio
2.602.603.733.381.733.81
Upgrade
Return on Equity (ROE)
-162.91%-162.91%-14.28%-71.75%-34.53%-0.44%
Upgrade
Return on Assets (ROA)
-21.83%-21.83%-4.04%-4.32%-10.40%0.19%
Upgrade
Return on Capital (ROIC)
-48.98%-48.98%-8.42%-8.28%-18.30%0.33%
Upgrade
Return on Capital Employed (ROCE)
-----0.40%
Upgrade
Earnings Yield
-30.58%-30.93%-3.58%-22.02%-15.02%-23.41%
Upgrade
FCF Yield
-4.50%-4.56%-15.58%-7.46%-16.89%-19.27%
Upgrade
Buyback Yield / Dilution
-0.74%-0.74%-1.02%-0.12%-0.77%-17.97%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.